Sec Form 4 Filing - Engelhart James @ Biohaven Pharmaceutical Holding Co Ltd. - 2022-01-06

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Engelhart James
2. Issuer Name and Ticker or Trading Symbol
Biohaven Pharmaceutical Holding Co Ltd. [ BHVN]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
Strategic Advisor
(Last) (First) (Middle)
C/O BIOHAVEN PHARMACEUTICALS, INC., 215 CHURCH STREET
3. Date of Earliest Transaction (MM/DD/YY)
01/06/2022
(Street)
NEW HAVEN, CT06510
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 01/06/2022 M 3,750 A $ 0 15,234( 1 ) D
Common Shares 01/06/2022 F 1,532( 2 ) D $ 123.86 13,702 D
Common Shares 01/07/2022 M 3,250 A $ 0 16,952 D
Common Shares 01/07/2022 F 1,279( 2 ) D $ 128.87 15,673 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Share Unit Award ( 3 ) 01/06/2022 M 3,750 ( 4 ) ( 5 ) Common Shares 3,750 $ 0( 3 ) 7,500 D
Employee Stock Option (Right to Buy) $ 128.87 01/07/2022 A 26,000 ( 6 ) 01/07/2032 Common Shares 26,000 $ 0 26,000 D
Restricted Share Unit Award ( 3 ) 01/07/2022 A 13,000 ( 7 ) ( 5 ) Common Shares 13,000 $ 0 13,000 D
Restricted Share Unit Award ( 3 ) 01/07/2022 M 3,250 ( 7 ) ( 5 ) Common Shares 3,250 $ 0 9,750 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Engelhart James
C/O BIOHAVEN PHARMACEUTICALS, INC.
215 CHURCH STREET
NEW HAVEN, CT06510
Strategic Advisor
Signatures
/s/ James Engelhart 01/07/2022
Signature of Reporting Person Date
Explanation of Responses:
( 1 )This balance includes 288 shares that were acquired through the Biohaven Employee Share Purchase Plan on May 31, 2021.
( 2 )No shares were sold - these shares were withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted share units.
( 3 )Each restricted share unit represents the contingent right to receive one common share of the Issuer.
( 4 )The reporting person was granted 15,000 restricted share units on January 6, 2021, vesting in four equal installments on January 6, 2021, 2022, 2023 and 2024, subject to the reporting person's continued service with the Issuer at each vesting date.
( 5 )Not applicable.
( 6 )The shares underlying this option vest in four equal installments on January 7, 2022, 2023, 2024 and 2025, subject to the reporting person's continuous service with the Issuer at each vesting date.
( 7 )The reporting person was granted 13,000 restricted share units on January 7, 2022, vesting in four equal installments on January 7, 2022, 2023, 2024 and 2025, subject to the reporting person's continued service with the Issuer at each vesting date.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.